obesity: A disorder involving an excessive amount of body fat.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
329 |
4. Check minimum number of eventsNone |
329 |
5. Include endpointsNone |
329 |
6. Filter based on genotype QC (FinnGen only) |
329 |
Control definitions (FinnGen only)
- Control exclude
- E4_OBESITY
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- E66
- Name in latin
- Obesitas medicamento provocata
Similar endpoints
↥List of similar endpoints to
Drug-induced obesity
based on the number of shared cases.
Similar with more cases:
- Obesity
- Obesity and other hyperalimentation
- Other nutritional deficiencies
- Endocrine, nutritional and metabolic diseases
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1947 | 1310 | 630 |
| Only index persons | 1879 | 1276 | 603 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.03 | 0.04 | 0.02 |
| Only index persons | 0.04 | 0.05 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 43.29 | 41.92 | 45.89 |
| Only index persons | 42.39 | 41.22 | 44.86 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 329 | 250 | 79 |
| Unadjusted period prevalence (%) | 0.07 | 0.09 | 0.03 |
| Median age at first event (years) | 46.50 | 43.57 | 55.76 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 300
- Matched controls
- 2998
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E66.1
ICD-10 Finland
Drug-induced obesity
+∞
323.0
300
*
E66.01
ICD-10 Finland
Obesity due to excess calories
439.1
232.3
207
15
E66.8
ICD-10 Finland
Other obesity
503.3
130.4
121
*
E66.9
ICD-10 Finland
Obesity, unspecified
562.8
87.9
83
*
E66.00
ICD-10 Finland
Metabolic syndrome
55.8
69.9
82
20
A10BA02
ATC
metformin; oral
8.5
55.7
149
311
JDF11
NOMESCO Finland
Laparoscopic gastric bypass
+∞
52.7
49
*
G47.3
ICD-10 Finland
Sleep apnoea
6.3
37.4
118
279
T82
ICPC
Obesity
21.7
36.5
54
30
E66
ICD-10 Finland
Obesity
16.4
35.9
59
44
E11.9
ICD-10 Finland
Type 2 diabetes mellitus, without complications
6.4
34.4
105
234
QBJ30
NOMESCO Finland
Correction of abdominal apron
165.9
29.2
30
*
103
Kela drug reimbursment
Diabetes, insulin-treated
4.9
28.5
111
319
Z71.3
ICD-10 Finland
Dietary counselling and surveillance
11.7
27.9
53
54
C03CA01
ATC
furosemide; systemic
5.2
27.3
97
250
215
Kela drug reimbursment
Diabetes, non-insulin-treated
4.8
26.7
106
307
E66.0
ICD-10 Finland
Obesity due to excess calories
+∞
26.4
25
*
E66.2
ICD-10 Finland
Extreme obesity with alveolar hypoventilation
+∞
25.4
24
*
T90
ICPC
Diabetes non-insulin dependent
4.8
24.6
95
264
310
Kela drug reimbursment
Orlistat, sibutramine and other major and expensive medicines used to treat obesity
61.4
24.5
28
5
112
Kela drug reimbursment
Severe psychotic and other severe mental disorders
7.3
24.4
62
103
RD210
NOMESCO Finland
NA
30.1
22.7
30
11
E11
ICD-10 Finland
Type 2 diabetes mellitus
5.3
21.6
72
168
B01AB05
ATC
enoxaparin; parenteral
3.6
21.4
125
497
285
Kela drug reimbursment
Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (adults)
13.4
21.2
37
31
SPAT1262
SPAT
Handing over of treatment supplies
4.7
21.1
80
215
SPAT1306
SPAT
Counselling and guidance related to nutrition and weight management
4.6
19.3
74
199
N02AX02
ATC
tramadol; systemic, rectal
3.1
19.1
153
751
SPAT1250
SPAT
Comprehensive monitoring of chronic illness
3.7
18.7
97
343
346
Kela drug reimbursment
Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (adults)
15.7
18.5
30
21
I10
ICD-10 Finland
Essential (primary) hypertension
3.0
18.5
165
862
A46
ICD-10 Finland
Erysipelas
5.3
18.3
60
136
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
3.2
17.3
115
486
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.9
16.4
145
734
N05AH03
ATC
olanzapine; systemic
5.6
16.0
48
98
R5140
NOMESCO Finland
Monitoring the use of the aid
5.7
15.9
47
94
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
5.0
15.8
53
123
N05AH04
ATC
quetiapine; oral
3.4
15.7
89
332
N05AX12
ATC
aripiprazole; systemic
6.6
15.0
39
66
F32.9
ICD-10 Finland
Depressive episode, unspecified
3.7
15.0
73
241
A10BB12
ATC
glimepiride; oral
9.2
14.9
31
37
205
Kela drug reimbursment
Chronic hypertension
3.4
14.7
80
287
N05AA02
ATC
levomepromazine; systemic
8.4
14.6
32
42
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.9
14.5
115
534
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
4.5
13.8
51
130
O24.4
ICD-10 Finland
Diabetes mellitus arising in pregnancy
4.6
13.7
50
126
JDF01
NOMESCO Finland
Laparoscopic gastroplasty
+∞
13.6
13
*
N06AB04
ATC
citalopram; systemic
2.9
13.6
100
440
160
Kela drug reimbursment
exenatide
27.2
13.5
18
7
F61.0
ICD-10 Finland
Mixed personality disorders
16.0
13.3
21
14
K80.2
ICD-10 Finland
Calculus of gallbladder without cholecystitis
4.0
13.2
56
163
WX404
NOMESCO Finland
Intravenous generell anesthesy
2.8
12.9
98
438
N06AX16
ATC
venlafaxine; oral
3.2
12.9
75
281
B03BA03
ATC
hydroxocobalamin; parenteral
7.1
12.7
31
48
XG466
NOMESCO Finland
Sleep oxymetry
18.3
12.7
19
11
N02BE01
ATC
paracetamol; systemic, rectal
3.6
12.7
272
2184
C07AB07
ATC
bisoprolol; oral
2.5
12.5
131
701
N05BA01
ATC
diazepam; systemic, rectal
3.5
12.5
62
206
E11.8
ICD-10 Finland
Type 2 diabetes mellitus, with unspecified complications
5.7
12.5
36
70
R03AC02
ATC
salbutamol; inhalant
2.4
12.3
188
1224
A08AB01
ATC
orlistat; oral
39.3
12.3
15
*
H03AA01
ATC
levothyroxine sodium; systemic
2.8
12.3
97
442
A10BK03
ATC
empagliflozin; oral
6.3
11.7
31
54
A10AE04
ATC
insulin glargine; parenteral
4.8
11.5
39
91
R4190
NOMESCO Finland
Nutritional therapy
8.2
11.4
25
33
F20.9
ICD-10 Finland
Schizophrenia, unspecified
10.2
10.9
21
22
A10BH01
ATC
sitagliptin; oral
4.8
10.9
36
82
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
4.5
10.6
38
94
A08AA10
ATC
sibutramine; oral
113.8
10.5
11
*
SFC01
NOMESCO Finland
Adjuvant procedure of filling therapy
2.5
10.5
100
501
L17
ICPC
Foot/toe symptom/complaint
2.6
10.3
89
422
N05AX08
ATC
risperidone; systemic
4.4
10.3
37
92
TPH04
NOMESCO Finland
Cathetrisation of vein
2.8
10.2
73
307
N05CD07
ATC
temazepam; oral
3.7
10.2
45
135
N05BA06
ATC
lorazepam; systemic, sublingual
5.1
10.0
31
66
S97
ICPC
Chronic ulcer skin
6.2
9.9
26
45
A08AA02
ATC
fenfluramine; oral (centrally acting antiobesity products)
27.0
9.9
13
5
SPAT1301
SPAT
No procedures
2.3
9.9
111
600
K02.1
ICD-10 Finland
Caries of dentine
2.2
9.9
199
1406
N06AX05
ATC
trazodone; oral
7.2
9.8
23
34
R4140
NOMESCO Finland
Psychotherapy
14.0
9.8
16
12
RD112
NOMESCO Finland
NA
56.8
9.7
11
*
N06AB03
ATC
fluoxetine; oral
3.0
9.7
61
237
A10AC01
ATC
insulin (human); parenteral (insulins and analog. for injection, intermediate-acting)
4.6
9.7
33
78
M17.0
ICD-10 Finland
Primary gonarthrosis, bilateral
3.4
9.6
49
165
A10BJ02
ATC
liraglutide; parenteral
15.7
9.6
15
10
N03AX16
ATC
pregabalin; oral
2.5
9.6
87
421
A02BC02
ATC
pantoprazole; systemic
2.2
9.5
202
1449
J01DB01
ATC
cefalexin; oral
2.9
9.5
265
2177
N02AA59
ATC
codeine, combinations excl. psycholeptics; systemic
2.2
9.5
156
998
O24.1
ICD-10 Finland
Diabetes mellitus in pregnancy: Pre-existing diabetes mellitus, non-insulin-dependent
103.1
9.5
10
*
SPAT1310
SPAT
Counselling related to known health issue
2.3
9.4
118
667
2780A
ICD-9 Finland
Obesity and other hyperalimentation, Obesity
+∞
9.4
9
*
SPAT1229
SPAT
Assessment of need for aid
4.3
9.4
35
90
B01AA03
ATC
warfarin; systemic
3.2
9.4
51
178
WX110
NOMESCO Finland
Local anesthesy
2.3
9.3
229
1748
JKA21
NOMESCO Finland
Laparoscopic cholecystectomy
3.4
9.3
47
157
C03DA01
ATC
spironolactone; oral
4.3
9.3
34
86
J45.9
ICD-10 Finland
Asthma, unspecified
2.7
9.2
71
312
N05BA04
ATC
oxazepam; oral
2.4
9.2
94
480
EBA05
NOMESCO Finland
Complicated extraction of tooth
2.6
9.2
75
340
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
3.5
9.1
43
136
WYA30
NOMESCO Finland
Preparations for expected poor cooperation
3.6
9.1
41
125
T81.4
ICD-10 Finland
Infection following a procedure, not elsewhere classified
3.3
9.1
47
160
R4160
NOMESCO Finland
Other therapy enhancing rehabilitation
7.8
9.1
20
27
M54.5
ICD-10 Finland
Low back pain
2.2
9.0
119
688
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
2.2
9.0
132
801
N02AJ06
ATC
codeine and paracetamol; systemic
2.2
9.0
129
775
J01FF01
ATC
clindamycin; systemic
2.3
8.9
98
518
WX290
NOMESCO Finland
Other blockade of nerve
2.1
8.8
159
1048
M79.6
ICD-10 Finland
Pain in limb
2.2
8.6
121
716
N05CF01
ATC
zopiclone; oral
2.2
8.6
102
559
F32.2
ICD-10 Finland
Severe depressive episode without psychotic symptoms
3.4
8.5
41
132
Z50.4
ICD-10 Finland
Psychotherapy, not elsewhere classified
20.7
8.5
12
6
A10BD07
ATC
metformin and sitagliptin; systemic
8.2
8.5
18
23
N03AG01
ATC
valproic acid; systemic, rectal
4.0
8.5
33
89
TLC00
NOMESCO Finland
Insertion of intrauterine device
3.4
8.5
41
133
M17.9
ICD-10 Finland
Gonarthrosis, unspecified
3.3
8.2
42
142
A08
ICPC
Swelling
7.2
8.2
19
28
R60.0
ICD-10 Finland
Localized oedema
3.4
8.2
40
131
L28
ICPC
Limited function/disability (L)
2.9
8.1
50
191
E28.2
ICD-10 Finland
Polycystic ovarian syndrome
9.3
8.1
16
18
C09AA05
ATC
ramipril; oral
2.6
8.1
62
270
F60.30
ICD-10 Finland
Emotionally unstable personality disorder, impulsive
7.6
8.1
18
25
A10BX04
ATC
[U] exenatide; parenteral
22.7
8.1
11
5
T36
ICD-10 Finland
Poisoning by systemic antibiotics
4.6
8.1
27
63
N03AX09
ATC
lamotrigine; oral
4.0
8.0
31
83
F31.9
ICD-10 Finland
Bipolar affective disorder, unspecified
5.7
8.0
22
41
M17.1
ICD-10 Finland
Other primary gonarthrosis
2.6
8.0
64
286
SPAT1249
SPAT
Treatment-related counselling outside office
2.0
8.0
135
857
EBA00
NOMESCO Finland
Extraction of tooth
2.1
7.9
113
668
A10BJ06
ATC
semaglutide; parenteral
9.8
7.9
15
16
X69
ICD-10 Finland
Intentional self-poisoning by and exposure to other and unspecified chemicals and noxious substances
5.6
7.9
22
42
J45
ICD-10 Finland
Asthma
3.1
7.8
44
158
M51.1
ICD-10 Finland
Lumbar and other intervertebral disc disorders with radiculopathy
2.7
7.8
55
229
A06AD11
ATC
lactulose; oral
3.1
7.8
43
152
SPAT1305
SPAT
Counselling and guidance related to physical exercise
3.2
7.8
41
142
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
3.1
7.7
43
153
R03AK06
ATC
salmeterol and fluticasone; inhalant
2.8
7.7
52
212
B01AB04
ATC
dalteparin; parenteral
6.0
7.7
20
35
N05AE04
ATC
ziprasidone; systemic
25.7
7.6
10
*
WYA05
NOMESCO Finland
Emergency visit or other similar visit involving procedures
2.0
7.6
162
1116
H02AB09
ATC
hydrocortisone; systemic
7.4
7.6
17
24
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.7
7.6
56
238
F33.2
ICD-10 Finland
Recurrent depressive disorder, current episode severe without psychotic symptoms
3.9
7.5
30
83
F33.9
ICD-10 Finland
Recurrent depressive disorder, unspecified
4.4
7.5
26
63
M04AA01
ATC
allopurinol; systemic
3.6
7.4
33
100
N05AB03
ATC
perphenazine; systemic, rectal
5.2
7.4
22
45
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
2.2
7.4
87
468
N02AA05
ATC
oxycodone; systemic
3.1
7.4
41
145
I50.9
ICD-10 Finland
Heart failure, unspecified
3.8
7.3
30
85
C10AA01
ATC
simvastatin; oral
2.1
7.3
97
552
SFA10
NOMESCO Finland
Fillning on one surface of tooth
2.0
7.3
179
1291
Y83
ICD-10 Finland
Surgical operation and other surgical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
3.6
7.3
32
96
RD140
NOMESCO Finland
NA
+∞
7.3
7
*
P06
ICPC
Sleep disturbance
3.0
7.3
42
154
SPAT1253
SPAT
Initiation, adjustment, discontinuation or repetition of medication
2.0
7.3
109
654
F29
ICD-10 Finland
Unspecified nonorganic psychosis
4.8
7.2
23
51
S18
ICPC
Laceration/cut
2.0
7.2
124
781
F31.7
ICD-10 Finland
Bipolar affective disorder, currently in remission
6.3
7.2
18
30
F31.30
ICD-10 Finland
Bipolar disorder Depressive episode without somatic syndrome
6.3
7.2
18
30
F60.31
ICD-10 Finland
Emotionally unstable personality disorder, borderline condition
8.2
7.2
15
19
WX722
NOMESCO Finland
PEEP
5.0
7.2
22
47
WZB00
NOMESCO Finland
Telephone receipt or other advice
2.1
7.1
105
622
C03EA01
ATC
hydrochlorothiazide and potassium-sparing agents; oral
2.8
7.1
48
194
J20.9
ICD-10 Finland
Acute bronchitis, unspecified
2.5
7.1
61
280
L02.2
ICD-10 Finland
Cutaneous abscess, furuncle and carbuncle of trunk
5.2
7.1
21
43
J01DA09
ATC
[U] cefadroxil; inhalant, oral
2.1
7.1
94
535
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
2.8
7.1
47
186
N05AH02
ATC
clozapine; systemic
7.3
7.1
16
23
C03AA03
ATC
hydrochlorothiazide; oral
4.0
7.1
27
72
SPAT1148
SPAT
Treatment of chronic ulcer or burn
3.1
7.1
39
137
A28
ICPC
Limited function/disability NOS
3.1
7.0
39
138
N06AX03
ATC
mianserin; oral
4.6
7.0
23
53
SGC10
NOMESCO Finland
Covering pulpa of tooth
2.9
7.0
43
163
R06.0
ICD-10 Finland
Dyspnoea
2.3
6.9
73
373
203
Kela drug reimbursment
Chronic asthma and similar chronic obstructive pulmonary diseases
2.3
6.9
69
347
JAD30
NOMESCO Finland
Repair of incisional hernia using prosthetic material
11.3
6.9
12
11
N04AA02
ATC
biperiden; systemic
7.5
6.8
15
21
IGY02
NOMESCO Finland
Psychiatric monitoring contact
7.5
6.8
15
21
A10BJ01
ATC
exenatide; parenteral
17.2
6.8
10
6
IER04
NOMESCO Finland
Rehabilitative psychiatric group intervention, functional
17.2
6.8
10
6
F20
ICD-10 Finland
Schizophrenia
41.0
6.8
8
*
B81
ICPC
Anaemia vit B12/folate deficiency
5.7
6.7
18
33
SPAT1234
SPAT
Support of social functional capacity
6.1
6.7
17
29
IFA99
NOMESCO Finland
Other psychiatric pharmacotherapy service
23.1
6.7
9
*
J01MA12
ATC
levofloxacin; systemic
2.4
6.7
59
278
Z71.8
ICD-10 Finland
Other specified counselling
2.1
6.7
86
482
SPAT1156
SPAT
Guidance concerning treatment of rash and skin
2.7
6.6
46
190
IFA01
NOMESCO Finland
Psychiatric pharmacotherapy plan, not specified
9.0
6.6
13
15
K43.9
ICD-10 Finland
Other and unspecified ventral hernia without obstruction or gangrene
5.3
6.6
19
38
N05AD01
ATC
haloperidol; systemic
7.1
6.6
15
22
F32.10
ICD-10 Finland
Moderate depressive episode without somatic syndrome
2.9
6.6
41
157
WX408
NOMESCO Finland
General anesthesy, balanced
2.1
6.5
88
501
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.3
6.5
60
289
A10BH05
ATC
linagliptin; oral
5.7
6.4
17
31
O24.0
ICD-10 Finland
Diabetes mellitus in pregnancy: Pre-existing diabetes mellitus, insulin-dependent
8.4
6.4
13
16
SGA01
NOMESCO Finland
Tooth opening as first aid
2.3
6.4
59
283
R06.5
ICD-10 Finland
Mouth breathing
3.3
6.4
31
102
N03AX11
ATC
topiramate; oral
5.0
6.3
19
40
F20.30
ICD-10 Finland
Undifferentiated schizophrenia continuous
9.6
6.3
12
13
A10BX01
ATC
guar gum; systemic
7.3
6.3
14
20
IEY05
NOMESCO Finland
Dedicated profession-specific psychiatric intervention, individual
5.2
6.3
18
36
IEY08
NOMESCO Finland
Psychiatric coaching, domestic and community skills
27.3
6.3
8
*
SPAT1256
SPAT
Intramuscular and subcutaneous injection
1.9
6.3
124
813
SPAT1008
SPAT
Photography of fundus of the eye or interpretation of photograph
5.6
6.2
17
32
F31.8
ICD-10 Finland
Other bipolar affective disorders
6.0
6.2
16
28
JN3BD
NOMESCO Finland
Extensive abdominal CT
2.7
6.2
43
177
R50.9
ICD-10 Finland
Fever, unspecified
2.6
6.2
48
208
D50.9
ICD-10 Finland
Iron deficiency anaemia, unspecified
3.4
6.2
28
87
F33.10
ICD-10 Finland
Recurrent depression, moderate episode without somatic syndrome
3.1
6.2
33
116
M54.4
ICD-10 Finland
Lumbago with sciatica
2.2
6.2
64
323
N06AA12
ATC
doxepin; systemic
4.2
6.1
22
56
K04.0
ICD-10 Finland
Pulpitis
2.7
6.1
42
171
E11.6
ICD-10 Finland
Type 2 diabetes mellitus, with other specified complications
12.9
6.1
10
8
TPH07
NOMESCO Finland
Cathetrisation of artery
3.0
6.1
34
121
LCA13
NOMESCO Finland
Curettage of cervix and body of uterus
3.5
6.1
27
83
N06AB06
ATC
sertraline; oral
2.5
6.0
45
194
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
105
369
3.71
25.18
2.4
1.6
1212.6
1273.5
nmol/l
0.27
89
273
191
979
3.27
24.61
5.6
4.9
34.7
36.4
g/l
4.10
181
926
83
256
4.00
23.95
5.5
7.4
1.0
1.1
mmol/l
0.70
76
233
176
911
3.00
21.40
2.7
1.8
90.1
96.2
pmol/l
1.11
116
452
135
615
3.03
20.51
4.0
3.9
8.4
11.5
mg/mmol
0.29
85
376
131
596
2.99
19.83
2.8
2.0
3.2
3.0
mg/l
0.49
114
513
119
518
3.03
19.44
1.7
1.4
19.6
21.4
nmol/l
0.73
102
448
199
1160
2.81
18.45
8.4
6.8
1.2
1.2
mmol/l
0.03
178
1001
193
1111
2.78
18.28
3.3
2.2
67.6
77.0
nmol/l
5.03
182
1005
184
1056
2.68
17.18
7.8
5.9
1.2
1.2
mmol/l
1.13
171
970
221
1448
2.60
14.83
6.7
4.5
6.7
6.4
mmol/l
1.21
209
1314
145
789
2.50
14.47
2.7
2.3
45.3
56.9
u/l
5.12
133
734
81
336
2.87
13.91
2.8
2.5
2.6
2.4
g/l
1.91
70
318
99
466
2.61
13.23
2.5
1.5
416.0
12438265.5
pmol/l
0.50
88
402
14
14
10.40
12.31
2.7
3.5
45.4
11.7
mu/l
1.02
14
14
302
2421
4.01
12.31
9.0
4.6
41.1
38.4
mmol/mol
5.24
291
2285
81
367
2.60
11.54
2.9
2.5
11.6
14.3
umol/l
2.97
74
339
265
2007
2.65
11.38
8.3
6.9
83.8
76.2
u/l
1.73
248
1885
144
859
2.20
10.86
3.1
3.0
30.4
30.0
u/l
0.05
135
822
139
824
2.19
10.58
3.1
3.4
2.3
2.4
mmol/l
1.23
121
731
280
2223
2.74
10.11
5.7
4.2
14.4
14.5
pmol/l
0.41
263
2038
54
213
2.84
9.99
2.4
2.4
0.2
0.2
g/l
1.52
49
199
16
25
6.68
9.90
19.5
19.6
1693.0
1515.3
nmol/l
0.22
16
25
99
525
2.27
9.79
3.2
3.1
1208.5
862.2
ng/l
0.59
77
431
194
1341
2.09
9.56
4.2
2.8
89.7
85.8
ug/l
0.09
179
1259
112
631
2.17
9.50
2.1
2.7
357.1
8114.7
umol/l
3.27
83
557
68
312
2.49
9.29
3.0
2.6
18.5
24.0
%
2.72
57
272
306
2601
3.52
8.70
6.1
3.8
6.3
5.7
mmol/l
8.77
286
2403
188
1324
1.98
8.35
5.3
5.9
10.3
10.1
umol/l
0.13
180
1247
213
1578
1.99
8.04
13.6
9.3
4.3
3.9
e9/l
1.58
186
1371
301
2592
2.89
7.21
4.6
3.5
1.5
1.2
mmol/l
11.19
278
2411
53
246
2.38
6.98
11.8
7.0
104.5
104.0
mmol/l
0.23
53
241
13
24
5.60
6.82
16.8
9.9
0.5
0.7
mmol/l
1.72
13
24
19
50
3.97
6.63
1.1
1.2
—
—
—
0
0
300
2616
2.67
6.31
7.0
4.9
1.8
1.8
mu/l
0.02
284
2420
47
219
2.34
6.12
10.7
9.4
1.4
1.1
mmol/l
0.22
39
174
175
1284
1.78
6.10
4.4
4.0
—
—
—
0
0
74
421
1.98
5.79
3.1
2.6
2.4
2.4
mmol/l
0.42
63
365
237
1923
1.83
5.65
4.2
2.9
57.2
38.2
u/l
1.44
226
1812
62
335
2.05
5.59
2.3
1.8
—
—
—
0
0
306
2728
2.74
5.50
5.8
4.3
2.7
2.8
mmol/l
1.87
287
2549
98
622
1.82
5.46
2.8
2.2
—
—
—
0
0
302
2680
2.55
5.41
5.0
3.9
1.3
1.5
mmol/l
22.38
280
2509
66
369
1.99
5.41
2.2
1.7
1.4
1.4
%
0.12
56
331
303
2695
2.57
5.36
5.2
3.9
4.4
4.8
mmol/l
8.77
285
2531
126
871
1.72
5.19
3.6
3.2
505.1
29.0
ng/l
0.48
84
508
31
130
2.53
5.06
14.3
8.4
0.8
0.7
%
0.25
31
130
26
101
2.71
4.94
1.7
1.5
—
—
—
0
0
34
153
2.36
4.79
1.8
1.5
—
—
—
0
0
94
610
1.76
4.79
1.7
1.7
1.2
0.9
mg/l
0.85
71
445
38
183
2.22
4.58
4.7
4.7
2.6
1.7
mmol/l
0.68
33
147
30
131
2.42
4.51
14.8
8.4
1.2
1.4
%
0.40
30
131
28
119
2.48
4.46
8.7
5.5
25.6
24.9
mmol/l
0.43
28
119
19
66
2.99
4.41
5.0
1.6
—
—
—
0
0
29
127
2.41
4.34
15.2
8.6
93.5
94.4
%
0.60
29
127
7
6
11.88
4.29
1.4
2.0
18.8
19.7
umol/l
—
7
6
35
169
2.20
4.20
3.8
4.5
87.3
80.0
ng/l
0.15
29
154
9
13
7.08
4.19
1.1
2.1
—
—
—
0
0
9
13
7.08
4.19
1.1
2.1
—
—
—
0
0
9
13
7.08
4.19
1.1
2.1
—
—
—
0
0
9
13
7.08
4.19
1.1
2.1
—
—
—
0
0
122
880
1.61
4.07
3.1
3.1
—
—
—
0
0
241
2055
1.65
3.87
4.7
3.7
15.2
9.7
mm/h
6.04
223
1913
36
185
2.06
3.70
3.7
3.8
4.5
4.6
pmol/l
0.30
31
165
20
80
2.60
3.62
2.1
1.6
—
—
—
0
0
316
2947
2.83
3.60
13.2
9.3
30.5
24.7
u/l
4.37
310
2849
7
9
7.92
3.57
1.0
1.6
—
—
—
0
0
7
9
7.92
3.57
1.0
1.6
—
—
—
0
0
42
233
1.92
3.50
3.8
2.1
30.2
33.2
u/l
0.20
33
199
9
18
5.11
3.39
1.0
1.2
—
—
—
0
0
49
289
1.82
3.38
5.1
3.7
28.5
33.0
%
3.55
36
187
7
10
7.12
3.38
1.0
2.3
—
—
—
0
0
7
10
7.12
3.38
1.0
2.3
—
—
—
0
0
20
83
2.50
3.37
2.3
1.9
—
—
—
0
0
17
65
2.70
3.36
1.6
1.4
—
—
—
0
0
286
2587
1.81
3.29
18.1
10.2
91.4
87.8
ml/min/173m2
1.88
237
2061
32
165
2.04
3.27
2.1
2.6
3.9
5.3
ug/l
0.64
25
148
41
231
1.89
3.27
2.2
1.8
—
—
—
0
0
303
2804
2.02
3.05
21.7
11.5
21.8
20.9
mg/l
0.20
277
2103
39
224
1.84
2.94
2.3
1.7
—
—
—
0
0
61
399
1.65
2.93
3.0
3.3
59.0
177.4
ng/l
1.37
41
272
58
375
1.66
2.91
2.6
2.8
5.9
2.9
e6/l
0.82
32
189
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
9
22
4.18
2.90
1.0
1.2
—
—
—
0
0
6
9
6.76
2.88
1.0
1.6
—
—
—
0
0
6
9
6.76
2.88
1.0
1.6
—
—
—
0
0
20
90
2.30
2.86
6.0
3.5
54.5
52.1
%
0.18
20
90
9
23
3.99
2.79
1.1
2.0
—
—
—
0
0
9
23
3.99
2.79
1.1
2.0
—
—
—
0
0
9
23
3.99
2.79
1.1
2.0
—
—
—
0
0
6
10
6.09
2.71
1.0
2.3
—
—
—
0
0
21
100
2.17
2.65
3.9
2.6
1.5
1.1
%
0.78
21
100
26
135
2.01
2.64
2.2
1.4
—
—
—
0
0
6
11
5.53
2.55
1.0
1.4
—
—
—
0
0
6
11
5.53
2.55
1.0
1.3
—
—
—
0
0
47
300
1.66
2.48
7.9
6.5
—
—
—
0
0
99
753
1.45
2.38
1.4
1.3
0.8
1.3
u/ml
0.98
34
205
45
287
1.66
2.38
2.8
2.8
6.0
5.9
umol/l
0.02
35
242
16
71
2.32
2.38
8.3
3.9
3.8
3.9
mmol/l
0.06
16
66
92
695
1.45
2.29
3.2
2.8
0.2
0.4
e6/l
0.43
71
510
161
1345
1.39
2.25
4.2
3.4
0.0
0.0
estimate
0.00
23
272
32
189
1.77
2.23
3.3
2.3
6165.5
5409.5
u/l
0.04
11
85
17
82
2.13
2.11
1.1
1.7
503.2
420.2
mg/l
0.34
17
77
5
10
5.06
2.08
1.0
1.2
—
—
—
0
0
5
10
5.06
2.08
1.0
1.2
—
—
—
0
0
58
411
1.50
1.98
2.7
2.7
0.6
0.9
e6/l
0.81
32
223
36
229
1.64
1.95
5.3
2.6
—
—
—
0
0
9
33
2.77
1.94
1.1
1.8
—
—
—
0
0
89
689
1.40
1.91
1.6
1.7
1.7
1.3
mmol/l
2.11
75
598
5
12
4.21
1.83
1.0
1.0
—
—
—
0
0
9
35
2.61
1.81
1.8
1.4
—
—
—
0
0
8
29
2.80
1.80
1.1
1.8
—
—
—
0
0
93
735
1.37
1.75
4.6
3.7
0.0
0.0
estimate
0.50
24
271
158
1353
1.32
1.74
5.6
4.7
0.0
0.0
estimate
0.50
25
276
5
13
3.89
1.72
1.0
1.5
—
—
—
0
0
10
42
2.42
1.69
1.2
1.4
—
—
—
0
0
7
25
2.84
1.66
1.0
1.4
339.9
410.7
pmol/l
—
7
20
6
20
3.04
1.59
1.2
1.1
—
—
—
0
0
158
1368
1.30
1.55
4.2
3.4
0.0
0.0
estimate
0.50
24
271
5
15
3.37
1.53
3.0
4.1
—
—
—
0
0
5
15
3.37
1.53
1.2
1.3
—
—
—
0
0
11
51
2.20
1.52
2.3
2.1
—
—
—
0
0
19
309
0.59
1.42
1.1
1.6
—
—
—
0
0
11
53
2.11
1.40
1.3
7.2
—
262.8
iu/ml
—
0
12
0
37
0.00
1.35
0.0
1.7
—
13.2
—
0
37
8
34
2.39
1.30
1.9
1.4
—
—
—
0
0
8
34
2.39
1.30
1.9
1.4
—
—
—
0
0
8
35
2.32
1.27
1.9
1.4
—
—
—
0
0
8
35
2.32
1.27
1.9
1.4
—
—
—
0
0
8
35
2.32
1.27
1.9
1.4
—
—
—
0
0
8
35
2.32
1.27
1.0
1.1
—
—
—
0
0
13
70
1.89
1.25
1.1
1.9
11.7
10.3
mg/l
0.36
13
64
14
79
1.81
1.19
1.1
1.4
—
—
—
0
0
11
57
1.96
1.18
2.5
1.7
—
—
—
0
0
7
136
0.50
1.12
1.3
1.6
—
—
—
0
0
18
278
0.63
1.12
1.3
1.5
—
—
—
0
0
85
706
1.28
1.11
1.5
1.6
—
—
—
0
0
7
32
2.21
1.08
1.0
1.2
—
—
—
0
0
9
46
1.98
1.04
1.2
4.2
—
877.0
—
0
5
25
353
0.68
1.03
5.8
4.2
16.7
21.3
%
—
9
173
9
47
1.94
1.03
1.3
1.3
—
—
—
0
0
9
47
1.94
1.03
1.3
1.3
—
—
—
0
0
18
265
0.66
0.92
1.6
1.6
—
—
—
0
0
18
265
0.66
0.92
2.7
2.8
0.6
0.8
ug/l
0.80
13
165
8
42
1.93
0.89
1.1
1.4
—
—
—
0
0
121
1072
1.20
0.86
4.8
3.5
—
—
—
0
0
13
80
1.65
0.86
1.2
1.1
—
—
—
0
0
26
191
1.39
0.80
1.8
2.3
77.4
73.2
ml/min/173m2
—
10
74
25
334
0.73
0.78
1.8
1.7
—
—
—
0
0
19
133
1.45
0.75
2.1
1.6
—
—
—
0
0
9
55
1.65
0.74
2.8
1.8
—
—
—
0
0
7
38
1.86
0.74
3.3
1.8
—
—
—
0
0
5
26
1.94
0.71
1.0
1.2
—
—
—
0
0
21
153
1.40
0.69
1.2
1.4
—
—
—
0
0
5
28
1.80
0.66
1.2
1.4
—
—
—
0
0
273
2632
1.22
0.65
25.0
12.5
40.2
40.0
%
0.19
195
2099
14
95
1.49
0.65
1.0
1.1
—
—
—
0
0
14
95
1.49
0.65
1.0
1.1
—
—
—
0
0
63
539
1.21
0.64
1.3
1.3
20.1
28.1
iu/ml
0.65
17
173
62
535
1.20
0.58
1.3
1.2
2.2
9.5
u/ml
2.81
23
220
13
90
1.46
0.56
1.7
2.2
86.2
94.2
%
0.39
13
84
6
37
1.63
0.56
1.0
1.1
—
—
—
0
0
12
84
1.44
0.50
1.5
1.6
—
256.0
—
0
5
7
47
1.50
0.48
1.7
1.3
—
—
—
0
0
32
265
1.23
0.46
1.2
1.2
101.6
167.8
iu/ml
—
9
121
7
51
1.38
0.44
1.3
1.2
—
—
—
0
0
13
173
0.74
0.43
1.4
1.5
—
—
—
0
0
11
150
0.72
0.42
1.2
1.4
—
—
—
0
0
11
150
0.72
0.42
1.2
1.4
—
—
—
0
0
12
161
0.74
0.42
1.3
1.5
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
11
149
0.73
0.41
1.2
1.4
—
—
—
0
0
11
149
0.73
0.41
1.2
1.4
—
—
—
0
0
8
112
0.71
0.38
1.9
1.6
—
—
—
0
0
5
78
0.64
0.36
1.6
1.3
—
—
—
0
0
39
443
0.86
0.33
4.0
4.5
1.5
2.7
ug/l
0.88
31
388
6
47
1.28
0.32
1.2
1.0
—
—
—
0
0
7
52
1.35
0.31
1.4
2.3
—
—
—
0
0
11
142
0.77
0.31
1.5
1.5
—
—
—
0
0
7
53
1.33
0.31
4.0
2.4
—
—
—
0
0
216
2092
1.09
0.31
3.6
3.6
—
—
—
0
0
60
547
1.12
0.30
2.3
2.1
—
—
—
0
0
21
176
1.21
0.29
1.0
1.0
—
—
—
0
0
5
72
0.69
0.26
1.2
1.4
—
—
—
0
0
5
39
1.29
0.23
1.0
1.1
—
—
—
0
0
13
107
1.22
0.22
1.4
2.1
—
—
—
0
0
5
42
1.19
0.21
1.2
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
4.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.9
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
21.6
—
0
11
0
11
0.00
0.21
0.0
4.0
—
—
—
0
0
5
43
1.17
0.21
4.0
1.6
—
—
—
0
0
9
115
0.78
0.20
2.1
1.7
—
—
—
0
0
26
234
1.12
0.17
4.5
4.0
3.6
27.4
ug/l
0.72
20
193
53
498
1.08
0.16
2.2
2.0
—
—
—
0
0
6
76
0.79
0.16
1.2
1.5
—
—
—
0
0
9
79
1.14
0.15
1.4
1.9
—
—
—
0
0
21
192
1.10
0.11
1.3
1.4
—
—
—
0
0
6
54
1.11
0.09
1.3
4.1
—
3.4
—
0
7
9
100
0.90
0.06
1.7
1.3
—
—
—
0
0
68
692
0.98
0.03
1.6
1.5
—
—
—
0
0
12
112
1.07
0.03
2.6
1.9
—
—
—
0
0
13
138
0.94
0.02
1.8
1.3
236.7
251.0
miu/ml
—
7
70
0
7
0.00
0.00
0.0
1.3
—
8.4
—
0
7
0
9
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
2.4
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
65.7
—
0
6
Mortality – FinRegistry
↥Association
Association between endpoint E4_OBESITYDRUG and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_OBESITYDRUG | 2.566 [2.01, 3.27] | < 0.001 |
| Birth year | 0.997 [0.99, 1.01] | 0.542 |
During the follow-up period (1.1.1998 — 31.12.2019), 125 out of 1189 females with E4_OBESITYDRUG died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_OBESITYDRUG | 3.083 [2.32, 4.1] | < 0.001 |
| Birth year | 0.989 [0.98, 1.0] | 0.065 |
During the follow-up period (1.1.1998 — 31.12.2019), 123 out of 581 males with E4_OBESITYDRUG died.
Mortality risk
Mortality risk for people of age
years, who have E4_OBESITYDRUG.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.326% | 0.507% |
| 5 | 1.67% | 3.295% |
| 10 | 4.356% | 8.667% |
| 15 | 8.38% | 15.952% |
| 20 | 13.586% | 26.563% |
Relationships between endpoints
↥Index endpoint: E4_OBESITYDRUG – Drug-induced obesity
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data